Brazilian Guideline on Menopausal Cardiovascular Health – 2024
Gláucia Maria Moraes de Oliveira, Maria Cristina Costa de Almeida, Carolina Artucio, Larissa Neto Espíndola, Maria Alayde Mendonça Rivera, Agnaldo Lopes da Silva Filho, Celi Marques-Santos, César Eduardo Fernandes, Carlos Japhet da Matta Albuquerque, Cláudia Maria Vilas Freire, Maria Cristina de Oliveira Izar, Maria Elizabeth Navegantes Caetano Costa, Marildes Luíza de Castro, Viviana de Mello Guzzo Lemke, Alexandre Jorge Gomes de Lucena, Andréa Araújo Brandão, Ariane Vieira Scarlatelli Macedo, Carísi Anne Polanczyk, Carla Janice Baister Lantieri, Eliana Aguiar Petri Nahás, Elizabeth Regina Giunco Alexandre, Érika Maria Gonçalves Campana, Érika Olivier Vilela Bragança, Fernanda Marciano Consolim‐Colombo, Imara Correia de Queiroz Barbosa, Iván Romero Rivera, Jaime Kulak, Lídia Zytynski Moura, Luciano de Mello Pompei, Luiz Francisco Baccaro, Márcia M. Barbosa, M. Rodrigues, Marco Aurélio Albernaz, Maria Sotera Paniagua de Decoud, Maria Sanali Moura de Oliveira Paiva, Martha Beatriz Sanchez-Zambrano, Milena dos Santos Barros Campos, Mónica Acevedo, M Ramirez, Olga Ferreira de Souza, Orlando Otávio de Medeiros, Regina Coeli Marques de Carvalho, Rogério Bonassi Machado, Sheyla Cristina Tonheiro Ferro da Silva, Thais de Carvalho Vieira Rodrigues, Walkíria Samuel Ávila, Lúcia Costa‐Paiva, Maria Celeste Osório Wender
Abstract
1. Introduction After the publication of the results from the Women’s Health Initiative (WHI) clinical trial in 2002 showing more risks than benefits to female health with estrogen (alone or combined with progestin) use to control menopausal signs and symptoms, there has been a progressive and sustained decline in the prescription of those drugs. – In the United States, there was an increase in the prescription of menopausal hormone therapy (MHT) from 16 million in 1966 to 90 million in [...]